Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-29

Clinical Trial Update: A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing belzutifan to everolimus in advanced renal cell carcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Afinitor (everolimus)
  • Welireg (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-29